南開科技大學圖書館 |

回首頁

Population science methods and approaches to aging and Alzheimer's disease and related dementias research /

紀錄類型:	書目-語言資料,印刷品 : 單行本
正題名/作者:	Population science methods and approaches to aging and Alzheimer's disease and related dementias research // edited by Chau Trinh-Shevrin.
其他作者:	Trinh-Shevrin, Chau,
出版者:	Hoboken, NJ :Jossey-Bass,c2024.
面頁冊數:	xxv, 147 p. :ill. ;24 cm.
標題:	Aging - Psychological aspects. -
ISBN:	9781394204144
ISBN:	9781394204168
ISBN:	9781394204151

Population science methods and approaches to aging and Alzheimer's disease and related dementias research /
Population science methods and approaches to aging and Alzheimer's disease and related dementias research /edited by Chau Trinh-Shevrin. - Hoboken, NJ :Jossey-Bass,c2024. - xxv, 147 p. :ill. ;24 cm.

Includes bibliographical references and index.

"Aging begins at birth. Yet most people only begin to recognize and struggle with the aging process when they observe and experience a loss of their own youthful vitality, the breakdown of their bodies, and changes in their appearances. In parallel, we see the reflection of these effects within our neighborhoods, communities, and society at large, producing new challenges for families and caregivers, health care providers, researchers, and policymakers. While national policies and programs, such as Medicare, are pivoting to become more cognizant and inclusive of aging-related conditions and the treatments and support needed by aging Americans and their care partners, there is an urgent need to focus attention and investment on population health approaches to address the unmet needs, sociocultural contexts, and health trajectories of older people. While a vast array of aging-related conditions can impact the daily activities and well-being of older people, Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) are among the most feared of these conditions. As AD/ADRD advances, acute fear gives way to chronic anxiety, anger, and withdrawal. Caregivers of people living with AD/ADRD may find the most painful aspects of this process to be observing their loved ones suffer and become mere shells of the people they once were. It is important to distinguish dementia from AD. Other forms of dementia include vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Cruetzfeldt-Jakob disease, Huntington's Disease, normal pressure hydrocephalus, and mixed dementia (i.e., a combination of two or more sources of dementia). Typically, this group of diseases is referred to as AD/ADRD. In addition to degenerative diseases, like AD or Parkinson's Disease, other causes of dementia may include chronic drug use, depression, infections, stroke, and vascular disease. AD is a disease of the brain and is progressively degenerative, impairing areas of the brain that include learning, thinking, and bodily functioning and leading to debilitation over time. AD is currently irreversible. Over the last two decades, there have been increasing and substantial investments in identifying and testing therapeutics to treat and potentially reverse AD. For example, researchers have focused on the role of plaque-forming beta-amyloid in the brain in accelerating AD-associated deterioration, leading to the development of monoclonal antibodies to the immune system to help clear beta-amyloid from the brain. An example of this type of drug is lecanamab (i.e., Lequembi), which received accelerated approval by the United States (U.S.) Federal Drug Administration (F.D.A.) in early 2023; previously, aducanemab (i.e., Aduhelm) was approved in 2021. None of these currently available therapies, however, has proven beneficial to all of the individuals who have participated in drug trials or to those who have been given these therapies in healthcare settings, indicating the need for more investment and focused research to better understand the mechanisms and expression of AD. In addition, social isolation and loneliness can impact risk for depression, cognitive decline, and risk for AD/ADRD. As research progresses, including more diverse communities in biomedical and community-based research is an urgent imperative. Clinical trials conducted to date have failed to achieve meaningful representation by minoritized and low-income communities, leading to results that are not generalizable to many of the Americans in greatest need of these therapies. Toward that end, financial resources and community-engaged strategies are needed to ensure that the promise of biomedical research and clinical trials is available to all. This Handbook aims to provide a starting point for clinicians and other practitioners eager to take on these challenges in innovative, meaningful ways, particularly in minoritized, limited English proficient, and low-income communities. The topics included here range from population health trends and approaches to understanding community and patient engagement to caregiver perspectives and emerging trends. The Handbook aims to serve as a primer, introducing fundamental aspects of population health and participatory approaches to reducing health disparities and advancing health equity in the context of aging-related research. Our hope is that this introduction to the landscape of aging research in the most vulnerable of our communities will facilitate creativity, compassion, and meaningful next steps in biomedical and socioecological research, community support, and clinical care"--

ISBN: 9781394204144NT2095

LCCN: 2023026146Subjects--Topical Terms:

150809
Aging
--Psychological aspects.

LC Class. No.: BF724.55.A35 / P67 2023

Dewey Class. No.: 155.67

Population science methods and approaches to aging and Alzheimer's disease and related dementias research /
LDR:05420cam a2200217 a 4500 001 1000134180
005 20240806094159.0
008 230612s2024 njua b 001 0 eng
010 $a 2023026146
020 $a 9781394204144 $q (pbk.) : $c NT2095
020 $a 9781394204168 $q (adobe pdf)
020 $a 9781394204151 $q (epub)
035 $a 23182512
040 $a DLC $b eng $c DLC $d DLC
042 $a pcc
050 0 0 $a BF724.55.A35 $b P67 2023
082 0 0 $a 155.67 $2 23/eng/20230927
245 0 0 $a Population science methods and approaches to aging and Alzheimer's disease and related dementias research / $c edited by Chau Trinh-Shevrin.
260 $a Hoboken, NJ : $b Jossey-Bass, $c c2024.
300 $a xxv, 147 p. : $b ill. ; $c 24 cm.
504 $a Includes bibliographical references and index.
520 $a "Aging begins at birth. Yet most people only begin to recognize and struggle with the aging process when they observe and experience a loss of their own youthful vitality, the breakdown of their bodies, and changes in their appearances. In parallel, we see the reflection of these effects within our neighborhoods, communities, and society at large, producing new challenges for families and caregivers, health care providers, researchers, and policymakers. While national policies and programs, such as Medicare, are pivoting to become more cognizant and inclusive of aging-related conditions and the treatments and support needed by aging Americans and their care partners, there is an urgent need to focus attention and investment on population health approaches to address the unmet needs, sociocultural contexts, and health trajectories of older people. While a vast array of aging-related conditions can impact the daily activities and well-being of older people, Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) are among the most feared of these conditions. As AD/ADRD advances, acute fear gives way to chronic anxiety, anger, and withdrawal. Caregivers of people living with AD/ADRD may find the most painful aspects of this process to be observing their loved ones suffer and become mere shells of the people they once were. It is important to distinguish dementia from AD. Other forms of dementia include vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Cruetzfeldt-Jakob disease, Huntington's Disease, normal pressure hydrocephalus, and mixed dementia (i.e., a combination of two or more sources of dementia). Typically, this group of diseases is referred to as AD/ADRD. In addition to degenerative diseases, like AD or Parkinson's Disease, other causes of dementia may include chronic drug use, depression, infections, stroke, and vascular disease. AD is a disease of the brain and is progressively degenerative, impairing areas of the brain that include learning, thinking, and bodily functioning and leading to debilitation over time. AD is currently irreversible. Over the last two decades, there have been increasing and substantial investments in identifying and testing therapeutics to treat and potentially reverse AD. For example, researchers have focused on the role of plaque-forming beta-amyloid in the brain in accelerating AD-associated deterioration, leading to the development of monoclonal antibodies to the immune system to help clear beta-amyloid from the brain. An example of this type of drug is lecanamab (i.e., Lequembi), which received accelerated approval by the United States (U.S.) Federal Drug Administration (F.D.A.) in early 2023; previously, aducanemab (i.e., Aduhelm) was approved in 2021. None of these currently available therapies, however, has proven beneficial to all of the individuals who have participated in drug trials or to those who have been given these therapies in healthcare settings, indicating the need for more investment and focused research to better understand the mechanisms and expression of AD. In addition, social isolation and loneliness can impact risk for depression, cognitive decline, and risk for AD/ADRD. As research progresses, including more diverse communities in biomedical and community-based research is an urgent imperative. Clinical trials conducted to date have failed to achieve meaningful representation by minoritized and low-income communities, leading to results that are not generalizable to many of the Americans in greatest need of these therapies. Toward that end, financial resources and community-engaged strategies are needed to ensure that the promise of biomedical research and clinical trials is available to all. This Handbook aims to provide a starting point for clinicians and other practitioners eager to take on these challenges in innovative, meaningful ways, particularly in minoritized, limited English proficient, and low-income communities. The topics included here range from population health trends and approaches to understanding community and patient engagement to caregiver perspectives and emerging trends. The Handbook aims to serve as a primer, introducing fundamental aspects of population health and participatory approaches to reducing health disparities and advancing health equity in the context of aging-related research. Our hope is that this introduction to the landscape of aging research in the most vulnerable of our communities will facilitate creativity, compassion, and meaningful next steps in biomedical and socioecological research, community support, and clinical care"-- $c Provided by publisher.
650 0 $a Aging $x Psychological aspects. $3 150809
650 0 $a Alzheimer's disease. $3 171670
650 0 $a Dementia. $3 171672
700 1 $a Trinh-Shevrin, Chau, $d 1972- $3 1000154176